New vaccine combo takes on rare belly cancer
NCT ID NCT07341360
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a cancer vaccine (Pseudovax) combined with an immune booster and an immunotherapy drug in 10 people with pseudomyxoma peritonei, a rare abdominal cancer that has come back or cannot be removed. The goal is to see if the treatment is safe and can reactivate the immune system to fight the cancer. Participants must have a specific gene mutation (GNAS) and have no other good treatment options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pseudovax (cancer vaccine), molgramostim (immune booster), and tislelizumab (immunotherapy)
What this could lead to
If it works, this could point toward a new treatment option for people with a rare abdominal cancer that has few alternatives.
What could go wrong
This is a very early, small trial with only 10 participants, so results may not apply widely. The treatment may cause side effects or fail to control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSEUDOMYXOMA PERITONEI are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Oslo University Hospital HF, Radium
RECRUITINGOslo, Oslo, 0379, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact